Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach
Autor: | Bernadett Szabados, Francesca Jackson-Spence, Thomas Powles, T. Butters, Wing K. Liu, Axel Bex, M. Grant, J. M. Lam |
---|---|
Rok vydání: | 2020 |
Předmět: |
Oncology
Nephrology medicine.medical_specialty Performance status business.industry Urology medicine.medical_treatment Hazard ratio 030232 urology & nephrology Cancer Disease medicine.disease Nephrectomy 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma 030220 oncology & carcinogenesis Internal medicine medicine Progression-free survival business |
Zdroj: | World Journal of Urology. 38:3199-3205 |
ISSN: | 1433-8726 0724-4983 |
DOI: | 10.1007/s00345-020-03107-0 |
Popis: | Metastatic renal cell carcinoma (mRCC) represents a significant and rising burden of disease, with rapidly evolving treatment modalities. The role of cytoreductive nephrectomy (CN) is controversial in this setting. As such, London Cancer has pursued a multidisciplinary team (MDT) approach when assessing suitability for surgery. A retrospective analysis of treatment-naive synchronous mRCC patients, managed via a renal-specialist MDT, was conducted between January 2015 and December 2018. An MDT selection algorithm for CN—using the International Metastatic Renal Cell Carcinoma Database Consortium score (IMDC), performance status and metastatic disease burden—was developed. 87 treatment-naive synchronous mRCC patients received either CN (n = 18), Systemic therapy (ST) alone (n = 43) or Best supportive care (BSC) (n = 26). Progression free survival (PFS) and overall survival (OS) were assessed. 51% and 39% were IMDC intermediate and poor risk. Median PFS was 28.6 months and 4.5 months in the CN group and ST alone group, respectively, Hazard Ratio for death was 3.63 [(95% CI 1.68–7.83) p |
Databáze: | OpenAIRE |
Externí odkaz: |